Leukapheresis Market by Product (Apheresis Machine, Leukocyte Filter, Column, Disposables), Leukopak (Mobilized, Non-Mobilized, Human Primary Cells), Application (Research, Therapeutic), End User (Hospitals, Research Institute) - Global Forecast to 2023
[194 Pages Report] The Leukapheresis products market was valued at USD 18.5 million in 2017 and is expected to reach USD 27.7 million by 2023, at a CAGR of 7.4%. Leukopaks are enriched leukapheresis products that contain higher concentrations of leukocytes. The Leukopaks market is expected to reach USD 445.6 million by 2023, at a CAGR of 46.4% during the forecast period. The base year considered for the study is 2017 and the forecast period includes 2018 to 2023.
Objectives of the Study
- To define, describe, and forecast the leukapheresis products market by type, application, end user, and region
- To define, describe, and forecast the leukopaks market by type, indication, end user, and region
- To provide detailed information regarding the major factors influencing market growth (drivers, restraints, opportunities, and industry-specific challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
- To forecast the size of the leukapheresis products market with respect toNorth America, Europe, Asia Pacific, and the Rest of the World
- To forecast the size of the leukopaks market with respect toNorth America, Europe, Asia Pacific, and the Rest of the World
- To analyze the opportunities in the market for stakeholders and to provide details of the competitive landscape for market leaders
- To profile key players in the leukapheresis products market and comprehensively analyze their core competencies
- To profile key players in the leukopaks market and comprehensively analyze their core competencies
- To track and analyze competitive developments such as R&D activities; product launches; acquisitions; expansions; and collaborations, agreements, and partnerships of the leading players in the leukapheresis (leukapheresis products and leukopaks) market
Market Drivers
Increasing incidence and prevalence of leukemia
Globally, the incidence of leukemia has risen significantly. According to the NIH National Cancer Institute in 2015, 405,815 people were suffering from leukemia in the US. According to NIH estimates, the number of new cases of leukemia has increased on an average rate of 0.3% each year over the last 10 years (from 2006 to 2015). The NIH also estimates that the number of new cases may reach 60,300 in 2018. According to the Leukemia & Lymphoma Society, from 2010 to 2014, leukemia was the sixth-most-common cause of cancer deaths globally.
Increasing number of blood donations
The global demand for blood and blood components is on the rise. In the US alone, ~44,000 units of blood are required every day in hospitals and emergency treatment facilities. Approximately 21 million units of blood components are transfused every year in the US. The requirement of leukocytes/WBCs is increasing with the increase in demand for leukopaks in clinical research and the rising number of clinical trials for the development of CAR-T therapy for leukemia.
Research Methodology
Top-down and bottom-up approaches were used to validate the size of leukapheresis products and leukopaks industry and estimate the size of other dependent submarkets. Various secondary sources such as directories, industry journals, databases such as D&B Hoovers, Bloomberg Business, and Factiva, and annual reports of the companies have been used to identify and collect information useful for the study of this market. Primary sources such as experts from both supply and demand sides have been interviewed to obtain and validate information as well as to assess dynamics of this market. The breakdown of profiles of primaries is shown in the figure below:
To know about the assumptions considered for the study, download the pdf brochure
Major players in the leukapheresis products market include Asahi Kasei Medical (Japan), Fresenius (Germany), Haemonetics (US), Terumo BCT (US), STEMCELL Technologies (Canada), and Macopharma (France). Some prominent players in the leukopaks market are HemaCare (US), AllCells (US), StemExpress (US), PPA Research Group (US), Key Biologics (US), Caltag Medsystem (UK), ZenBio (US), Precision for Medicine (US), and BioIVT (US).
Target Audience:
- Apheresis Device Manufacturers and Distributors
- Leukapheresis Product Manufacturers and Distributors
- Leukopak Manufacturers and Distributors
- Pharmaceutical and Biotechnological Companies
- Healthcare Service Providers (including Hospitals and Transfusion Centers)
- Cancer Treatment Centers
- Blood Component Providers & Blood Centers
- Contract Research Organizations
- Academic And Research Institutes
- Government Associations
- Market Research and Consulting Firms
- Venture Capitalists and Investors
Competitive Landscape
Product Launches and Enhancements
|
Month & Year |
Company Name |
Segment |
Product |
|
May 2018 |
Key Biologics (US) |
Diseased Leukopaks |
Fresh and frozen whole leukapheresis sourced product i.e. leukopaks from patients with hematologic malignancies, Multiple Myeloma, Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Acute Lymphocytic Leukemia. These leukopaks act as an important patient material for research and development of CAR-T therapies. |
|
July 2017 |
BioIVT (US) |
Diseased Leukopaks |
BioIVT expanded its leukopaks portfolio of disease state materials i.e. serums from rare diseases, such as HIV-1, HIV-2, dengue, Zika, and malaria. |
Source: Press Releases
Agreements, Partnerships, and Collaborations
|
Month & Year |
Nature of Alliance |
Company 1 |
Company 2 |
Description |
|
February 2018 |
Collaboration |
Terumo BCT (US) |
Stafa Cellular Therapy (US) |
According to this collaboration, Terumo BCT will act as a distributor for Stafa Cellular Therapy and will expand its access to StafaCT software to healthcare organizations. With the association of StafaCT software with Terumo BCTs apheresis systems, Terumo BCT can also streamline workflows, collection, and management of data throughout the continuum of care. |
|
February 2018 |
Partnership |
HemaCare Corporation (US) |
Charles River Laboratories International Inc. (US) |
To integrate HemaCares peripheral blood mononuclear cells (PBMCs) into Charles Rivers NCG/PBMC Select Humanization Kit |
Source: Press Releases
Mergers and Acquisitions
|
Month & Year |
Nature of Alliance |
Company 1 |
Company 2 |
Description |
|
April 2017 |
Acquisition |
BioreclamationIVT (US) |
Asterand Bioscience (US) |
To widen its disease-state biospecimen capabilities, particularly in oncology, and expand its scientific service offerings for diagnostic and drug development researchers |
|
July 2015 |
Merger |
BioreclamationIVT (US) |
ILSBio, LLC (US) |
To enhance its disease state and clinical samples product line by providing frozen and FFPE tumor samples, tissue extractions, and other oncology-related biospecimens including leukopaks |
Source: Press Releases
Expansions
|
Month & Year |
Company |
Description |
|
April 2018 |
Fresenius Kabi (Germany) |
Expanded its production site for medical devices in Haina, Dominican Republic (US). The Haina plant manufactures and exports apheresis systems for plasma and platelet collection as well as medical devices for blood separation. With this new production facility, the company aims to enhance its production capabilities and meet the increasing demand for apheresis systems. |
|
January 2017 |
AllCells (US) |
Expanded its clinical division-LeukoLab with the opening of a second collection facility in Quincy, Massachusetts, US |
Source: Press Releases
Scope of the Report:
The research report categorizes the market into the following segments and subsegments:
Leukapheresis Products Market, By Type
- Leukapheresis Devices
- Apheresis Devices
- Leukapheresis Columns & Cell Separators
- Leukoreduction Filters
- Leukapheresis Disposables
Leukapheresis Products Market, By Application
- Research Applications
- Therapeutic Applications
Leukapheresis Products Market, By End User
- Blood Component Providers and Blood Centers
- Academic and Research Institutes
- Pharmaceutical and Biotechnology Companies
- Hospitals and Transfusion Centers
Leukopaks Market, By Type
- Mobilized Peripheral Blood Leukopaks
- Non-mobilized Peripheral Blood Leukopaks
- Diseased Leukopaks
- Isolated PBMCs
Leukopaks Research Application Market, By Indication
- Acute Lymphocytic Leukemia
- Non-Hodgkin Lymphoma
- Multiple Myeloma
- Chronic Lymphocytic Leukemia
- Hepatocellular Carcinoma
- Pancreatic Cancer
- Other Indications (colorectal cancer, neuroblastoma, breast cancer, and acute myeloid leukemia)
Leukopaks Market, By End User
- Academic and Research Institutes
- Pharmaceutical and Biotechnology Companies
- Contract Research Organizations
Leukapheresis Market, by Region
- North America
- US
- Canada
- Europe
- UK
- Germany
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- China
- Rest of Asia Pacific
- Rest of World
The global leukapheresis products market is projected to reach USD 27.7 million by 2023 from USD 19.4 million in 2018, at a CAGR of 7.4%. Leukopaks are enriched leukapheresis products that contain higher concentrations of leukocytes. The global leukopaks market is projected to reach USD 445.6 million by 2023, at a CAGR of 46.4%. Factors contributing to the growth of these markets include the increasing incidence and prevalence of leukemia, growing demand for leukopaks for research applications, and increasing blood donations. The report analyzes the global leukapheresis products market by type, application, end user, and region.
On the basis of type of leukapheresis products, the leukapheresis disposables segment is estimated to account for the largest share of the leukapheresis products market in 2018. The large share of this segment can be attributed to the repeated consumption of disposables in leukapheresis procedures. The increasing applications of leukapheresis procedures for the isolation of primary cells from blood for cell therapy research applications is primarily driving the growth of this market segment during the forecast period.
Based on applications, the research applications segment is expected to account for the largest share of the global leukapheresis products market in 2018. The large share of this segment can be attributed to the growing adoption of leukapheresis products in research activities propelled by increasing research activities being undertaken for cancer, immunology, infectious diseases, drug discovery, regenerative medicine, and cell-based therapies.
By end user, the blood component providers & blood centers segment is expected to account for the largest share of the global leukapheresis products market in 2018. Growth in this market is primarily driven by the increasing number of blood donations, growing demand for leukopaks for the development of CAR-T therapy, and rising demand for leukopaks in clinical conditions like cancer.
The report also covers the global leukopaks market by type, indication, end user, and region. By type of leukopaks, the mobilized leukopaks segment is estimated to account for the largest share of the leukopaks market in 2018. The large share can be attributed to the increasing demand for low granulocyte and low hematocrit contamination, high cell viability, and an increase in CD34+ cell frequencies for the development of immunotherapies.
The academic & research institutes segment is expected to register the highest CAGR during the forecast period in the leukopaks market, by end user. The increasing industry-academic partnership for researching cell-based cancer therapies is driving the growth of leukopaks market for academic and research institutes, as leukopak constitutes the primary requirement of any type of research in cell biology and cancer immunotherapy.
Geographically, the global leukapheresis products and leukopaks market is segmented into North America, Europe, Asia Pacific, and Rest of the World. In 2018, Asia Pacific is expected to account for the largest share of the leukapheresis products and leukopaks market, followed by North America and Europe. APACs prominence in this market is mainly due to the increase in Regenerative Medicine research in the region, growth in the number of clinical trials for CAR-T therapy, and the presence of leading pharma and biotech companies focusing on cell therapy research.
The prominent players in the global leukapheresis products market are Asahi Kasei Medical (Japan), Fresenius (Germany), Haemonetics (US), Terumo BCT (US), STEMCELL Technologies (Canada), and Macopharma (France). Some prominent players in the leukopaks market are HemaCare (US), AllCells (US), StemExpress (US), PPA Research Group (US), Key Biologics (US), Caltag Medsystem (UK), ZenBio (US), Precision for Medicine (US), and BioIVT (US),
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
Table of Contents
1 Introduction (Page No. - 18)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Years Considered for the Study
1.3.2 Markets Covered
1.4 Currency
1.5 Limitations
1.6 Stakeholders
2 Research Methodology (Page No. - 23)
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Key Industry Insights
2.2 Market Size Estimation
2.2.1 Bottom-Up Approach
2.2.2 Top-Down Approach
2.3 Market Breakdown and Data Triangulation
2.4 Assumptions for the Study
3 Executive Summary (Page No. - 35)
4 Premium Insights (Page No. - 42)
4.1 Leukapheresis Products Market
4.1.1 Leukapheresis Products Market: Overview
4.1.2 Leukapheresis Products Market, By End User & Region (2017)
4.1.3 Geographic Snapshot of the Leukapheresis Products Market (2017)
4.1.4 Geographic Mix: Leukapheresis Products Market, 20182023 (USD Million)
4.1.5 Leukapheresis Products Market: Developing vs Developed Markets, 2018 vs 2023 (USD Million)
4.2 Leukopaks Market
4.2.1 Leukopaks Market: Overview
4.2.2 Leukopaks Market, By Type & Region (2017)
4.2.3 Geographic Snapshot of the Leukopaks Market (2017)
4.2.4 Geographic Mix: Leukopaks Market, 20182023 (USD Million)
4.2.5 Leukopaks Market: Developing vs Developed Markets, 2018 vs 2023 (USD Million)
5 Market Overview (Page No. - 51)
5.1 Introduction
5.2 Market Dynamics: Impact Analysis
5.2.1 Market Drivers
5.2.1.1 Increasing Incidence and Prevalence of Leukemia
5.2.1.2 Increasing Number of Blood Donations
5.2.1.3 Demand for Leukopaks in Clinical Research
5.2.2 Market Restraints
5.2.2.1 High Cost of Therapeutic Leukapheresis and Leukopaks
5.2.2.2 Stringent Donor Recruitment Criteria
5.2.2.3 Dearth of Skilled Professionals and Low Adoption of Therapeutic Leukapheresis
5.2.2.4 Complications Associated With Therapeutic Leukapheresis
5.2.3 Market Opportunities
5.2.3.1 Leukapheresis for Pediatric Patients
5.2.3.2 Emerging Economies and Increasing Investments From Academic Institutes, Pharma-Biotech Companies, and Leading Players
5.2.4 Market Challenges
5.2.4.1 High Cost of Cellular Immunotherapies
5.2.4.2 Blood Transfusion Safety in Developing Countries
6 Industry Insights (Page No. - 59)
6.1 Industry Trends
6.1.1 Increasing Number of Collaborations Among Pharma and Biotech Companies
6.2 Leukopaks: Pricing Analysis
6.3 Regulatory Analysis
6.3.1 US
6.3.2 Europe
6.3.3 Japan
7 Leukapheresis Products Market, By Type (Page No. - 64)
7.1 Introduction
7.2 Leukapheresis Devices
7.2.1 Apheresis Devices
7.2.2 Leukapheresis Columns & Cell Separators
7.2.3 Leukoreduction Filters
7.3 Leukapheresis Disposables
8 Leukapheresis Products Market, By Application (Page No. - 75)
8.1 Introduction
8.2 Research Applications
8.3 Therapeutic Applications
9 Leukapheresis Products Market, By End User (Page No. - 80)
9.1 Introduction
9.2 Blood Component Providers and Blood Centers
9.3 Academic and Research Institutes
9.4 Pharmaceutical and Biotechnology Companies
9.5 Hospitals and Transfusion Centers
10 Leukopaks Market (Page No. - 88)
10.1 Introduction
10.2 Leukopaks Market, By Type
10.2.1 Mobilized Peripheral Blood Leukopaks
10.2.2 Non-Mobilized Peripheral Blood Leukopaks
10.2.3 Diseased Leukopaks
10.2.4 Isolated Pbmcs
10.3 Leukopaks Research Application Market, By Indication
10.4 Leukopaks Market, By End User
10.4.1 Introduction
10.4.2 Academic & Research Institutes
10.4.3 Pharmaceutical and Biotechnology Companies
10.4.4 Contract Research Organizations
11 Geographic Analysis (Page No. - 102)
11.1 Introduction
11.2 North America
11.2.1 US
11.2.2 Canada
11.3 Europe
11.3.1 UK
11.3.2 Germany
11.3.3 Spain
11.3.4 RoE
11.4 Asia Pacific
11.4.1 China
11.4.2 Japan
11.4.3 Rest of Asia Pacific
11.5 Rest of the World
12 Competitive Landscape (Page No. - 144)
12.1 Introduction
12.2 Product Portfolio Matrix
12.3 Market Share Analysis
12.3.1 Leukapheresis Products
12.3.2 Leukopaks
12.4 Competitive Situations and Trends
12.4.1 Product Launches and Enhancements
12.4.2 Agreements, Partnerships, and Collaborations
12.4.3 Mergers and Acquisitions
12.4.4 Expansions
13 Company Profiles (Page No. - 152)
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*
13.1 Asahi Kasei Medical Co., Ltd. (A Subsidiary of Asahi Kasei Corporation)
13.2 Fresenius Se & Co. KGaA
13.3 Haemonetics Corporation
13.4 Hemacare Corporation
13.5 Key Biologics, LLC.
13.6 Terumo BCT
13.7 ALLCells, LLC.
13.8 Stemexpress, LLC.
13.9 Stemcell Technologies, Inc.
13.10 Caltag Medsystems Limited
13.11 Zenbio, Inc.
13.12 Precision for Medicine, Inc.
13.13 PPA Research Group, Inc.
13.14 Bioivt
13.15 Macopharma SA
*Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View Might Not Be Captured in Case of Unlisted Companies.
14 Appendix (Page No. - 184)
14.1 Insights of Industry Experts
14.2 Discussion Guide
14.3 Knowledge Store: Marketsandmarkets Subscription Portal
14.4 Related Reports
14.5 Author Details
List of Tables (134 Tables)
Table 1 Standard Currency Conversion Rates
Table 2 Incidence of Leukemia, By Country
Table 3 Collection of Whole Blood Units, By Country, 20152016 (Million Units)
Table 4 Cost of Leukopaks, By Type
Table 5 Donor Selection Criteria
Table 6 Frequency of Blood Donations From Healthy Donations
Table 7 Recent Initiatives for Development of Car T Therapy
Table 8 Recent Pharma-Biotech Collaborations for Development of Car T Therapy
Table 9 Asp of Non-Mobilized Leukopaks
Table 10 Asp of Mobilized Leukopaks
Table 11 Asp of Mobilized Isolated Cells
Table 12 List of Fda Approved Car T Therapeutics
Table 13 Leukapheresis Products Market, By Type, 20162023 (USD Million)
Table 14 Leukapheresis Products Market, By Country, 20162023 (USD Million)
Table 15 Leukapheresis Devices Market, By Type, 20162023 (USD Million)
Table 16 Leukapheresis Devices Market, By Country, 20162023 (USD Million)
Table 17 Leading Manufacturers Offering Apheresis Devices
Table 18 Apheresis Devices Market, By Country, 20162023 (USD Million)
Table 19 Leading Manufacturers of Leukapheresis Columns & Cell Separators
Table 20 Leukapheresis Columns & Cell Separators Market, By Country, 20162023 (USD Million)
Table 21 Leading Manufacturers of Leukoreduction Filters
Table 22 Leukoreduction Filters Market, By Country, 20162023 (USD Million)
Table 23 Leukapheresis Disposables Market, By Country, 20162023 (USD Million)
Table 24 Leukapheresis Products Market, By Application, 20162023 (USD Million)
Table 25 Number of Clinical Trials Based on Car T-Cell Therapy, 2013 to 2017
Table 26 Leukapheresis Products Market for Research Applications, By Country, 20162023 (USD Million)
Table 27 Leukapheresis Products Market for Therapeutic Applications, By Country, 20162023 (USD Thousand)
Table 28 Leukapheresis Products Market, By End User, 20162023 (USD Million)
Table 29 Leukapheresis Products Market for Blood Component Providers and Blood Centers, By Country, 20162023 (USD Million)
Table 30 Leukapheresis Products Market for Academic and Research Institutes, By Country, 20162023 (USD Million)
Table 31 Leading Pharma-Biotech Companies Involved in the Development of Car-T Technologies
Table 32 Leukapheresis Products Market for Pharmaceutical and Biotechnology Companies, By Country, 20162023 (USD Million)
Table 33 Number of Hospitals Performing Blood Transfusions, By Region, 2015
Table 34 Leukapheresis Products Market for Hospitals and Transfusion Centers, By Country, 20162023 (USD Million)
Table 35 Leukopaks Market, By Type, 20162023 (USD Million)
Table 36 Leukopaks Market, By Country, 20162023 (USD Million)
Table 37 Mobilized Pb Leukopaks Market, By Country, 20162023 (USD Million)
Table 38 Comparative Analysis of Mobilized Pb Leukopaks and Non-Mobilized Pb Leukopaks
Table 39 Non-Mobilized Pb Leukopaks Market, By Country, 20162023 (USD Million)
Table 40 Diseased Leukopaks Market, By Country, 20162023 (USD Million)
Table 41 Isolated Pbmcs Market, By Country, 20162023 (USD Million)
Table 42 Leukopaks Research Application Market, By Indication, 20162023 (USD Million)
Table 43 Leukopaks Market, By End User, 20162023 (USD Million)
Table 44 Leukopaks Market for Academic and Research Institutes, By Country, 20162023 (USD Million)
Table 45 Leukopaks Market for Pharmaceutical and Biotechnology Companies, By Country, 20162023 (USD Million)
Table 46 Leukopaks Market for Contract Research Organizations, By Country, 20162023 (USD Million)
Table 47 Leukapheresis Products Market, By Region, 20162023 (USD Million)
Table 48 Leukopaks Market, By Region, 20162023 (USD Million)
Table 49 North America: Leukapheresis Products Market, By Country, 20162023 (USD Million)
Table 50 North America: Leukapheresis Products Market, By Type, 20162023 (USD Million)
Table 51 North America: Leukapheresis Devices Market, By Type, 20162023 (USD Million)
Table 52 North America: Leukapheresis Products Market, By Application, 20162023 (USD Million)
Table 53 North America: Leukapheresis Products Market, By End User, 20162023 (USD Million)
Table 54 North America: Leukopaks Market, By Country, 20162023 (USD Million)
Table 55 North America: Leukopaks Market, By Type, 20162023 (USD Million)
Table 56 North America: Leukopaks Market, By End User, 20162023 (USD Million)
Table 57 US: Key Macroindicators
Table 58 US: Leukapheresis Products Market, By Type, 20162023 (USD Million)
Table 59 US: Leukapheresis Devices Market, By Type, 20162023 (USD Million)
Table 60 US: Leukapheresis Products Market, By Application, 20162023 (USD Million)
Table 61 US: Leukapheresis Products Market, By End User, 20162023 (USD Million)
Table 62 US: Leukopaks Market, By Type, 20162023 (USD Million)
Table 63 US: Leukopaks Market, By End User, 20162023 (USD Million)
Table 64 Canada: Key Macroindicators
Table 65 Canada: Leukapheresis Products Market, By Type, 20162023 (USD Million)
Table 66 Canada: Leukapheresis Devices Market, By Type, 20162023 (USD Thousand)
Table 67 Canada: Leukapheresis Products Market, By Application, 20162023 (USD Thousand)
Table 68 Canada: Leukapheresis Products Market, By End User, 20162023 (USD Thousand)
Table 69 Canada: Leukopaks Market, By Type, 20162023 (USD Million)
Table 70 Canada: Leukopaks Market, By End User, 20162023 (USD Million)
Table 71 Europe: Number of Registered Car Therapy Clinical Trials, By Country, 20132017
Table 72 Europe: Leukapheresis Products Market, By Country, 20162023 (USD Million)
Table 73 Europe: Leukapheresis Products Market, By Type, 20162023 (USD Million)
Table 74 Europe: Leukapheresis Devices Market, By Type, 20162023 (USD Million)
Table 75 Europe: Leukapheresis Products Market, By Application, 20162023 (USD Million)
Table 76 Europe: Leukapheresis Products Market, By End User, 20162023 (USD Million)
Table 77 Europe: Leukopaks Market, By Type, 20162023 (USD Million)
Table 78 Europe: Leukopaks Market, By End User, 20162023 (USD Million)
Table 79 UK: Key Macroindicators
Table 80 UK: Leukapheresis Products Market, By Type, 20162023 (USD Million)
Table 81 UK: Leukapheresis Devices Market, By Type, 20162023 (USD Million)
Table 82 UK: Leukapheresis Products Market, By Application, 20162023 (USD Thousand)
Table 83 UK: Leukapheresis Products Market, By End User, 20162023 (USD Million)
Table 84 Germany: Key Macroindicators
Table 85 Germany: Leukapheresis Products Market, By Type, 20162023 (USD Million)
Table 86 Germany: Leukapheresis Devices Market, By Type, 20162023 (USD Million)
Table 87 Germany: Leukapheresis Products Market, By Application, 20162023 (USD Thousand)
Table 88 Germany: Leukapheresis Products Market, By End User, 20162023 (USD Million)
Table 89 Spain: Key Macroindicators
Table 90 Spain: Leukapheresis Products Market, By Type, 20162023 (USD Million)
Table 91 Spain: Leukapheresis Devices Market, By Type, 20162023 (USD Million)
Table 92 Spain: Leukapheresis Products Market, By Application, 20162023 (USD Thousand)
Table 93 Spain: Leukapheresis Products Market, By End User, 20162023 (USD Million)
Table 94 RoE: Leukapheresis Products Market, By Type, 20162023 (USD Million)
Table 95 RoE: Leukapheresis Devices Market, By Type, 20162023 (USD Million)
Table 96 RoE: Leukapheresis Products Market, By Application, 20162023 (USD Million)
Table 97 RoE: Leukapheresis Products Market, By End User, 20162023 (USD Million)
Table 98 APAC: Leukapheresis Products Market, By Country, 20162023 (USD Million)
Table 99 APAC: Leukapheresis Products Market, By Type, 20162023 (USD Million)
Table 100 APAC: Leukapheresis Devices Market, By Type, 20162023 (USD Million)
Table 101 APAC: Leukapheresis Products Market, By Application, 20162023 (USD Million)
Table 102 APAC: Leukapheresis Products Market, By End User, 20162023 (USD Million)
Table 103 APAC: Leukopaks Market, By Country, 20162023 (USD Million)
Table 104 APAC: Leukopaks Market, By Type, 20162023 (USD Million)
Table 105 APAC: Leukopaks Market, By End User, 20162023 (USD Million)
Table 106 China: Key Macroindicators
Table 107 China: Leukapheresis Products Market, By Type, 20162023 (USD Million)
Table 108 China: Leukapheresis Devices Market, By Type, 20162023 (USD Million)
Table 109 China: Leukapheresis Products Market, By Application, 20162023 (USD Million)
Table 110 China: Leukapheresis Products Market, By End User, 20162023 (USD Million)
Table 111 China: Leukopaks Market, By Type, 20162023 (USD Million)
Table 112 China: Leukopaks Market, By End User, 20162023 (USD Million)
Table 113 Japan: Key Macroindicators
Table 114 Japan: Leukapheresis Products Market, By Type, 20162023 (USD Million)
Table 115 Japan: Leukapheresis Devices Market, By Type, 20162023 (USD Million)
Table 116 Japan: Leukapheresis Products Market, By Application, 20162023 (USD Thousand)
Table 117 Japan: Leukapheresis Products Market, By End User, 20162023 (USD Million)
Table 118 RoAPAC: Leukapheresis Products Market, By Type, 20162023 (USD Million)
Table 119 RoAPAC: Leukapheresis Devices Market, By Type, 20162023 (USD Million)
Table 120 RoAPAC: Leukapheresis Products Market, By Application, 20162023 (USD Million)
Table 121 RoAPAC: Leukapheresis Products Market, By End User, 20162023 (USD Million)
Table 122 RoAPAC: Leukopaks Market, By Type, 20162023 (USD Million)
Table 123 RoAPAC: Leukopaks Market, By End User, 20162023 (USD Million)
Table 124 RoW: Leukapheresis Products Market, By Type, 20162023 (USD Million)
Table 125 RoW: Leukapheresis Devices Market, By Type, 20162023 (USD Million)
Table 126 RoW: Leukapheresis Products Market, By Application, 20162023 (USD Million)
Table 127 RoW: Leukapheresis Products Market, By End User, 20162023 (USD Million)
Table 128 RoW: Leukopaks Market, By Type, 20162023 (USD Million)
Table 129 RoW: Leukopaks Market, By End User, 20162023 (USD Million)
Table 130 Growth Strategy Matrix
Table 131 Product Launches and Enhancements (2015 June 2018)
Table 132 Agreements, Partnerships, and Collaborations (2015June 2018)
Table 133 Mergers and Acquisitions (2015June 2018)
Table 134 Expansions (2015June 2018)
List of Figures (49 Figures)
Figure 1 Research Design
Figure 2 Primary Sources
Figure 3 Breakdown of Primary Interviews (Supply Side): By Company Type, Designation, and Region
Figure 4 Breakdown of Primary Interviews (Demand Side): By End User, Designation, and Region
Figure 5 Data Triangulation Methodology
Figure 6 Leukapheresis Disposables to Dominate the Leukapheresis Products Market During the Forecast Period
Figure 7 Apheresis Devices to Dominate the Leukapheresis Devices Market During the Forecast Period
Figure 8 Research Applications to Register Highest Growth in the Leukapheresis Products Market During the Forecast Period
Figure 9 Blood Component Providers & Blood Centers to Account for the Largest Share of the Leukapheresis Products Market in 2018
Figure 10 Mobilized Pb Leukopaks to Dominate the Leukopaks Market During 20182023
Figure 11 Acute Lymphocytic Leukemia to Dominate the Leukopaks Research Application Market, By Indication, During the Forecast Period
Figure 12 Academic & Research Institutes to Register Highest Growth in the Leukopaks Market During the Forecast Period
Figure 13 Geographic Snapshot: Leukapheresis Products Market
Figure 14 Geographic Snapshot: Leukopaks Market
Figure 15 Increasing Adoption of Therapeutic Leukapheresis Procedures to Drive Market Growth
Figure 16 Blood Component Providers & Blood Centers Held the Largest Share of the Leukapheresis Market in 2017
Figure 17 The US Accounted for the Largest Share of the Leukapheresis Products Market in 2017
Figure 18 APAC to Grow at the Highest CAGR During the Forecast Period
Figure 19 Developing Markets to Register Higher Growth During the Forecast Period
Figure 20 Growing Number of Clinical Trials for the Development of Car-T Therapies to Drive Market Growth
Figure 21 Mobilized Leukopaks Held the Largest Share of the Leukopaks Market in 2017
Figure 22 The US Accounted for the Largest Share of the Leukopaks Market in 2017
Figure 23 APAC to Grow at the Highest CAGR During the Forecast Period
Figure 24 Developing Markets to Register Higher Growth During the Forecast Period
Figure 25 Growth in Number of Immunotherapy Trials
Figure 26 Leukapheresis Disposables to Dominate the Leukapheresis Products Market During the Forecast Period
Figure 27 Apheresis Devices Dominated the Leukapheresis Products Market in 2017
Figure 28 Research Applications to Dominate the Leukapheresis Products Market From 2018 to 2023
Figure 29 Blood Component Providers and Blood Centers Estimated to Be the Largest End Users of Leukapheresis Products During the Forecast Period
Figure 30 Mobilized Pb Leukopaks Segment Will Continue to Dominate the Leukopaks Market During the Forecast Period
Figure 31 Number of Car-T Cell Therapy Clinical Trials Across the Globe
Figure 32 Acute Lymphocytic Leukemia Segment Dominated the Leukopaks Research Application Market in 2018
Figure 33 Academic & Research Institutes Segment to Register the Highest CAGR During the Forecast Period
Figure 34 Leukapheresis Products Market: Geographic Growth Opportunities
Figure 35 Leukopaks Market: Geographic Growth Opportunities
Figure 36 North America: Leukapheresis Products Market Snapshot
Figure 37 North America: Leukopaks Market Snapshot
Figure 38 Number of Registered Car Therapy Clinical Trials in the Us, 20132017
Figure 39 APAC: Leukapheresis Products Market Snapshot
Figure 40 APAC: Leukopaks Market Snapshot
Figure 41 Key Developments of Major Players Between 2014 and 2017
Figure 42 Leukapheresis Products Market Share Analysis, By Key Player, 2017
Figure 43 Leukopaks Market Share Analysis, By Key Player, 2017
Figure 44 Asahi Kasei Corporation: Company Snapshot (2017)
Figure 45 Fresenius Medical Care: Company Snapshot (2017)
Figure 46 Fresenius Kabi: Company Snapshot (2017)
Figure 47 Haemonetics Corporation: Company Snapshot (2018)
Figure 48 Hemacare Corporation: Company Snapshot (2017)
Figure 49 Terumo BCT: Company Snapshot (2016)
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Leukapheresis Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Growth opportunities and latent adjacency in Leukapheresis Market